SLYND

Peak

drospirenone

NDAORALTABLET
Approved
May 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
17

Clinical Trials (5)

NCT05985590Phase 1Completed

A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants

Started Aug 2023
37 enrolled
Healthy Volunteers
NCT03126097Phase 1Terminated

A Study to Investigate the Interaction Between JNJ-64155806 and Ethinylestradiol/Drospirenone in Healthy Females

Started Apr 2017
18 enrolled
Healthy
NCT03111511Phase 1Completed

A Study in Healthy Female Participants to Investigate the Effect of JNJ-56136379 at Steady-state on the Single-dose Pharmacokinetics of Ethinylestradiol and Drospirenone (Oral Contraceptive) and on the Single-dose Pharmacokinetics of Midazolam (Probe Substrate for Cytochrome P450 3A4)

Started Mar 2017
18 enrolled
Healthy
NCT02885454Phase 1Completed

To Evaluate the Effects of Odalasvir and AL-335 With Simeprevir on the Single-Dose Pharmacokinetics of Ethinylestradiol and Drospirenone in Healthy Female Participants

Started Aug 2016
24 enrolled
Healthy
NCT01902264Phase 3Completed

Study of Treatment With the Combination of Drospirenone Plus Ethinyl Estradiol Plus Levomefolate Calcium in Mexican Women Seeking Contraception

Started Aug 2013
34 enrolled
Contraception

Loss of Exclusivity

LOE Date
Jun 28, 2031
64 months away
Patent Expiry
Jun 28, 2031

Patent Records (5)

Patent #ExpiryTypeUse Code
10179140
Jun 28, 2031
U-2553
10603281
Jun 28, 2031
U-2553
10849857
Jun 28, 2031
Product
U-2553
10987364
Jun 28, 2031
Product
11123299
Jun 28, 2031
Product